Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.

ABSTRACT:

Background

Expression of the oestrogen receptor (ER) in breast cancer predicts benefit from endocrine therapy. Minimising the frequency of false negative ER status classification is essential to identify all patients with ER positive breast cancers who should be offered endocrine therapies in order to improve clinical outcome. In routine oncological practice ER status is determined by semi-quantitative methods such as immunohistochemistry (IHC) or other immunoassays in which the ER expression level is compared to an empirical threshold. The clinical relevance of gene expression-based ER subtypes as compared to IHC-based determination has not been systematically evaluated. Here we attempt to reduce the frequency of false negative ER status classification using two gene expression ap

SUBMITTER: Li Q 

PROVIDER: S-EPMC2995741 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature